IR@PKUHSC  > 北京大学第三临床医学院  > 血液内科
学科主题临床医学
Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia
Wu, Sun1; Dai, Yifeng2,3; Zhang, Yuan1; Wang, Xiufeng1; Wang, Lihua1; Ma, Dong1; Zhang, Lingxiu1; Pang, Yifan4; Jiao, Yang5,6; Niu, Mingshan7; Xu, Kailin7; Ke, Xiaoyan8,9; Shi, Jinlong10,11,12; Cheng, Zhiheng10; Fu, Lin7,8,9,13
通讯作者Cheng, Zhiheng(10)
刊名CANCER GENE THERAPY
2018-08-01
DOI10.1038/s41417-018-0028-z
25期:7页:207-213
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biotechnology & Applied Microbiology ; Oncology ; Genetics & Heredity ; Medicine, Research & Experimental
研究领域[WOS]Biotechnology & Applied Microbiology ; Oncology ; Genetics & Heredity ; Research & Experimental Medicine
关键词[WOS]HEMATOPOIETIC-CELL TRANSPLANTATION ; ACUTE MYELOGENOUS LEUKEMIA ; EUROPEAN LEUKEMIANET ; CHEMOTHERAPY ; MANAGEMENT ; EXPRESSION ; REMISSION ; AML
英文摘要

The mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia (IR-AML), which accounts for a substantial number of AML, are unclear. In order to explore the prognostic significance of the mutational spectrum in IR-AML, 106 IR-AML patients were collected from The Cancer Genome Atlas database. Sixty-two patients underwent chemotherapy-only, forty-four proceeded to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Fifty-five patients had more than five recurrent genetic mutations. NPM1 had the highest mutation frequency, followed by DNMT3A, FLT3, RUNX1, IDH2, IDH1, and TET2. In all patients, allo-HSCT was an independent favorable factor for EFS and OS (P = 0.036, P = 0.001, respectively); age >= 60 years, FLT3-ITD and mutations in DNMT3A and RUNX1 were independent risk factors for survival (all P < 0.05). In the chemotherapy-only group, multivariate analysis showed that age 60 years was an independent risk factor for EFS and OS (P = 0.008, P = 0.017, respectively). In the allo-HSCT group, multivariate analysis indicated that MLL-PTD was an independent risk fact for EFS (P = 0.037), FLT3-ITD and RUNX1 mutations independently contributed to poor OS (P = 0.035, P = 0.014, respectively). In conclusion, older age was an important risk factor for IR-AML patients undergoing chemotherapy-only; FLT3-ITD, MLL-PTD and RUNX1 mutations were significant risk factors for IR-AML patients who received allo-HSCT.

语种英语
WOS记录号WOS:000443568300005
通讯作者邮箱zhihengcheng@foxmail.com
第一作者单位Xinxiang Med Univ, Affiliated Hosp 1, Dept Hematol, Weihui 453100, Peoples R China
通讯作者单位Henan Univ, Huaihe Hosp, Translat Med Ctr, Kaifeng 475000, Peoples R China
ISSN0929-1903
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/143001
专题北京大学第三临床医学院_血液内科
作者单位1.William Beaumont Hosp, Dept Med, Royal Oak, MI 48073 USA;
2.Xinxiang Med Univ, Affiliated Hosp 1, Dept Hematol, Weihui 453100, Peoples R China;
3.Shantou Univ, Lab Environm Med & Dev Toxicol, Med Coll, Shantou 515041, Peoples R China;
4.Univ Med Ctr Groningen, Dept Pathol & Med Biol, Div Med Biol, Immunoendocrinol, Groningen, Netherlands;
5.Zhejiang Univ, Life Sci Inst, Hangzhou 310058, Zhejiang, Peoples R China;
6.Zhejiang Univ, Innovat Ctr Cell Signaling Network, Hangzhou 310058, Zhejiang, Peoples R China;
7.Xuzhou Med Univ, Affiliated Hosp, Dept Hematol, Xuzhou 221002, Jiangsu, Peoples R China;
8.Peking Univ, Hosp 3, Dept Hematol, Beijing 100191, Peoples R China;
9.Peking Univ, Hosp 3, Lymphoma Res Ctr, Beijing 100191, Peoples R China;
10.Henan Univ, Huaihe Hosp, Translat Med Ctr, Kaifeng 475000, Peoples R China;
11.Chinese Peoples Liberat Army Gen Hosp, Dept Biomed Engn, Beijing 100853, Peoples R China;
12.Chinese Peoples Liberat Army Gen Hosp, Dept Med Big Data, Beijing 100853, Peoples R China;
13.Henan Univ, Dept Hematol, Huaihe Hosp, Kaifeng 475000, Peoples R China
推荐引用方式
GB/T 7714
Wu, Sun,Dai, Yifeng,Zhang, Yuan,et al. Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia[J]. CANCER GENE THERAPY,2018,25(7):207-213.
APA Wu, Sun.,Dai, Yifeng.,Zhang, Yuan.,Wang, Xiufeng.,Wang, Lihua.,...&Fu, Lin.(2018).Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia.CANCER GENE THERAPY,25(7),207-213.
MLA Wu, Sun,et al."Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia".CANCER GENE THERAPY 25.7(2018):207-213.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wu, Sun]的文章
[Dai, Yifeng]的文章
[Zhang, Yuan]的文章
百度学术
百度学术中相似的文章
[Wu, Sun]的文章
[Dai, Yifeng]的文章
[Zhang, Yuan]的文章
必应学术
必应学术中相似的文章
[Wu, Sun]的文章
[Dai, Yifeng]的文章
[Zhang, Yuan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。